Scientific paper - Original scientific paper
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
European Journal of Preventive Cardiology, 28 (2021), 1; 33-43. https://doi.org/10.1177/2047487320941987

(ODYSSEY OUTCOMES Committees and Investigators) Diaz, Rafael; Li, Qian H; Bhatt, Deepak L; Bittner, Vera A; Baccara-Dinet, Marie T; Goodman, Shaun G; Jukema, J Wouter; Kimura, Takeshi; Parkhomenko, Alexander; Pordy, Robert; Reiner, Željko; Roe, Matthew T; Szarek, Michael; Tse, Hung-Fat; White, Harvey D; Zahger, Doron; Zeiher, Andreas M; Schwartz, Gregory G; Steg, Ph Gabriel More authors...

Cite this document

Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara Dinet, M. T., Goodman, S. G. ... Steg, P. G. (2021). Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 28. (1), 33-43. doi: 10.1177/2047487320941987

Diaz, Rafael, et al. "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial." European Journal of Preventive Cardiology, vol. 28, no. 1, 2021, pp. 33-43. https://doi.org/10.1177/2047487320941987

Diaz, Rafael, Qian H Li, Deepak L Bhatt, Vera A Bittner, Marie T Baccara Dinet, Shaun G Goodman, J Wouter Jukema, et al. "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial." European Journal of Preventive Cardiology 28, no. 1 (2021): 33-43. https://doi.org/10.1177/2047487320941987

Diaz, R., et al. (2021) 'Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial', European Journal of Preventive Cardiology, 28(1), pp. 33-43. doi: 10.1177/2047487320941987

Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara Dinet MT, Goodman SG, and sur.. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology [Internet]. 2021 March 23 [cited 2022 June 25];28(1):33-43. doi: 10.1177/2047487320941987

R. Diaz, et al., "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial", European Journal of Preventive Cardiology, vol. 28, no. 1, pp. 33-43, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:183800. [Accessed: 25 June 2022]

Please login to the repository to save this object to your list.